New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Lyra Therapeutics, Inc.
LYRA
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

17M

Biotechnology

Next Earning date - 05 Nov 2024

17M

Biotechnology

Next Earning date - 05 Nov 2024

0.26USD
Shape0.00 ( 0.79%)
Market Open
favorite-chart

Relative Strenght

6
favorite-chart

Volume Buzz

-20%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

96%

Quote Panel

Shape
Updated October 25, 2024
1W 4.51 % 1M 5.63 % 3M -17.10 % 1Y -92.30 %

Key Metrics

Shape
  • Market Cap

    16.69M


  • Shares Outstanding

    65.46M


  • Share in Float

    56.00M


  • Dividende

    0


  • Earning Date

    05 Nov 2024


  • Price Target

    0.255


  • Average Volume

    996892


  • Beta

    -0.017


  • Range

    0.211-6.79


  • Industry

    Biotechnology


  • Website

    https://lyratherapeutics.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

9.17x

P/S Ratio

0.54x

P/B Ratio

1.2

Debt/Equity

-5570.9%

Net Margin

$-1.6

EPS

How LYRA compares to sector?

P/E Ratio

Relative Strength

Shape

LYRA

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$772K

Shape29%

2025-Revenue

$0.80

Shape-7%

2025-EPS

$154K

Shape99%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Jefferies

downgrade

Previous: Not converted

2024-05-07

Now: Hold

BTIG

downgrade

Previous: Buy

2024-05-06

Now: Neutral

BTIG

downgrade

Previous: Buy

2024-05-06

Now: Reduce

William Blair

downgrade

Previous: Not converted

2024-05-06

Now: Market Perform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.40
vs -0.85

Q4.22

arrow
arrow

N/A

-0.36
vs -1.05

Q1.23

arrow
arrow

N/A

-0.44
vs -0.54

Q2.23

arrow
arrow

N/A

-0.33
vs -0.43

Q3.23

arrow
arrow

N/A

-0.27
vs -0.40

Q4.23

arrow
arrow

N/A

-0.22
vs -0.36

Q1.24

arrow
arrow

N/A

-0.35
vs -0.44

Q2.24

arrow
arrow

N/A

-0.29
vs -0.33

Q3.24

arrow
arrow

N/A

-0.21
vs -0.27

Q4.24

arrow
arrow

N/A

-0.19
vs -0.22

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+2464%

359K  vs 14K

Q4.22

arrow
arrow

-96%

11K  vs 271K

Q1.23

arrow
arrow

-92%

410K  vs 5.4M

Q2.23

arrow
arrow

+13%

458K  vs 407K

Q3.23

arrow
arrow

+52%

544K  vs 359K

Q4.23

arrow
arrow

+1227%

146K  vs 11K

Q1.24

arrow
arrow

+30%

532K  vs 410K

Q2.24

arrow
arrow

+31%

598K  vs 458K

Q3.24

arrow
arrow

-42%

315.6K  vs 544K

Q4.24

arrow
arrow

+122%

324.4K  vs 146K

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-16%

-0.16
vs -0.13

Q4.22

arrow
arrow

-18%

-0.18
vs -0.16

Q1.23

arrow
arrow

-25%

-0.25
vs -0.18

Q2.23

arrow
arrow

-16%

-0.16
vs -0.25

Q3.23

arrow
arrow

-19%

-0.19
vs -0.16

Q4.23

arrow
arrow

-17%

-0.17
vs -0.19

Q1.24

arrow
arrow

-29%

-0.29
vs -0.17

Q2.24

arrow
arrow

-155%

-1.55
vs -0.29

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

36

36
vs 32

13%

Q4.22

arrow
arrow

39

39
vs 36

8%

Q1.23

arrow
arrow

32

32
vs 39

-18%

Q2.23

arrow
arrow

41

41
vs 32

28%

Q3.23

arrow
arrow

47

47
vs 41

15%

Q4.23

arrow
arrow

63

63
vs 47

34%

Q1.24

arrow
arrow

82

82
vs 63

30%

Q2.24

arrow
arrow

53

53
vs 82

-35%

Earnings Growth

Latest News